Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer

Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer

Abstract Background This psychometric analysis generated evidence to support the use of the Functional Assessment of Cancer Therapy item GP5 (GP5) as a measure of tolerability and confirms the appropriateness of categorizing “high side-effect burden” using a rating of 3 or 4 (score ranges 0–4) in pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Antoine Regnault, Laurine Bunod, Angely Loubert, Marcia S. Brose, Lisa M. Hess, Patricia Maeda, Yan Lin, Rebecca M. Speck, Adrienne M. Gilligan, Nalin Payakachat
Format: Article
Language:English
Published: SpringerOpen 2024-12-01
Series:Journal of Patient-Reported Outcomes
Subjects:
Medullary thyroid cancer
Patient-reported tolerability
Psychometric analysis
FACT item GP5
Online Access:https://doi.org/10.1186/s41687-024-00823-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41687-024-00823-8

Similar Items